Enhancing Muscle Health and Metabolism in Pre-frail Middle-aged and Older Adults

June 13, 2023 updated by: National Yang Ming University

Enhancing Muscle Health and Metabolism in Pre-frail Middle-aged and Older Adults: A Randomized Controlled Trial Investigating the Benefits of Protein-enriched Supplementation and Weekly Exercise

To evaluate the effects of protein-enriched soup plus exercise on muscle mass and muscle strength.

Besides, the investigators use the valued-based healthcare standard set as well as the Center for Epidemiological Studies-Depression, Charlson's comorbidity index Montreal Cognitive Assessment , and Mini Nutritional Assessment as outcome measures and to use the trial in validate additional supplement protein-enriched soup plus exercise could improve the vitality and health of mid-aged and old adults.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

With aging, functions of every organs become to decline. Muscle mass, is one of the decline. According to previous research, adults would lose 40% among from aged 20 to 70. If muscle mass decline combining with the decline of muscle strength is so called Sarcopenia.When muscle mass decline, infectious risk gets higher, and resilience after illness gets lower. In addition, activity and life quality are also responsible for falling, cognitive difficulty, disability and mortality among seniors. We hope to find out the etiologies of Sarcopenia through this program and develop prevention strategy and model to mollify the the negative effect of rapid aging society.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan
        • National Yang Ming Chiao Tung University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. People who aged 50-75 years
  2. Patients with following characteristics:
  3. feeling loss in activity
  4. detecting decline in self's walking speed.
  5. feeling tired of doing everything.
  6. having fell in last year.
  7. People willing to follow the program and cooperate with us for following tracking.
  8. People who are neither vegan nor vegetarian
  9. People agree and be able to sign the informed consent.
  10. the protein of the daily meal are less than 1.0g/kg

Exclusion Criteria:

  1. People cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets.
  2. People with any disease affecting their limbs, including:
  3. having fracture on limbs in the past 6 months
  4. having severe arthritis in the past 6 months
  5. any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
  6. People with intermittent limp caused by peripheral artery diseases
  7. People with weak control of mental disorder
  8. People with weak control of Cardiopulmonary disease
  9. People with weak control of Malignant tumor
  10. People with weak control of kidney diseases (eGFR <60ml/min/1.73)
  11. People with Visual impairment and Hearing disorder which cannot help to complete the program.
  12. People who have underwent hormone treatment and planned to undergo hormone treatment during program session.
  13. Any other condition that PI recognized as not suitable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Usual care group
The control group only performed routine data collection and gave them dietary suggestion.
Experimental: Protein-enriched soup group
Protein-enriched soup /day for use as a supplement with meals and strength training /week
The participants in experimental group have a protein-enriched soup a day and do exercise a week

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes from baseline physical function after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by hand grip, 6-minute walk distance, six-meter walking speed, 5 times sit-to-stand
baseline, 4, 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes form baseline QUALITY OF LIFE after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by the 36-Item Short Form Health Survey (SF-36), ranged 0-100, higher values represent a better condition
baseline, 4, 12 weeks
Change from baseline Nutrition intake after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by Mini-nutritional assessment questionnaire. ranged 0-30, higher values represent a better condition
baseline, 4, 12 weeks
Change from baseline depression after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition
baseline, 4, 12 weeks
Change from baseline cognitive ability after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by Montreal Cognitive Assessment (MoCA) , ranged 0-30, higher values represent a better condition
baseline, 4, 12 weeks
Change from baseline body composition analysis after 12 weeks
Time Frame: baseline, 4, 12 weeks
measured by RASM
baseline, 4, 12 weeks
Change from baseline concentration of Total Cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Total Cholesterol after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Triglyceride after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Triglyceride after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
baseline, 4, 12 weeks
Change in International Physical Activity Questionnaire (IPAQ) after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change in physical activity measured by IPAQ, indicates that spent being physically active thin the prior 7 days.There are no established thresholds for presenting MET-minutes, the IPAQ Research Committee proposes that reported as comparisons of median values and interquartile ranges for different populations from baseline to 12 weeks in all participants.
baseline, 4, 12 weeks
Change from baseline numbers of Complete blood count after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline numbers of Complete blood count after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Albumin after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Albumin after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of blood urea nitrogen after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of blood urea nitrogen after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Creatinin after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Creatinin after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Fasting glucose after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Fasting glucose after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Fasting insulin after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Fasting insulin after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of Leptin after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of Leptin after 12 weeks
baseline, 4, 12 weeks
Change from baseline concentration of urine protein after 12 weeks
Time Frame: baseline, 4, 12 weeks
Change from baseline concentration of urine protein after 12 weeks
baseline, 4, 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Liang-Kung Chen, MD.PhD., Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 11, 2021

Primary Completion (Actual)

January 4, 2023

Study Completion (Actual)

January 4, 2023

Study Registration Dates

First Submitted

April 13, 2023

First Submitted That Met QC Criteria

April 13, 2023

First Posted (Actual)

April 25, 2023

Study Record Updates

Last Update Posted (Actual)

June 15, 2023

Last Update Submitted That Met QC Criteria

June 13, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Weakness

Clinical Trials on protein-enriched soup

Subscribe